<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157971</url>
  </required_header>
  <id_info>
    <org_study_id>21134</org_study_id>
    <secondary_id>NCI-2021-09185</secondary_id>
    <secondary_id>21134</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT05157971</nct_id>
  </id_info>
  <brief_title>Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial tests the safety, side effects, and best dose of venetoclax in combination&#xD;
      with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with&#xD;
      newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may stop the growth of cancer&#xD;
      cells by blocking Bcl-2, a protein needed for cancer cell survival. The C10403 regimen is&#xD;
      composed of the chemotherapy drugs cytarabine, cyclophosphamide, daunorubicin,&#xD;
      mercaptopurine, pegaspargase, vincristine, and methotrexate, all which work in different ways&#xD;
      to stop the growth of cancer cells, either by killing the cells, by stopping them from&#xD;
      dividing, or by stopping them from spreading. It also consists of prednisone, which is an&#xD;
      anti-inflammatory drug that lowers the body's immune response and is used with other drugs in&#xD;
      the treatment of some types of some types of cancer. This study may help researchers learn if&#xD;
      adding venetoclax to the pediatric-inspired C10403 regimen can be tolerated and help treat&#xD;
      older patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and tolerability of combining venetoclax with the C10403 regimen&#xD;
      backbone during induction and consolidation in newly diagnosed adults with B cell acute&#xD;
      lymphoblastic leukemia (ALL).&#xD;
&#xD;
      II. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose/schedule&#xD;
      (RP2D) of venetoclax in combination with the C10403 regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate complete response (CR) after induction. II. To estimate composite CR (CR or CR&#xD;
      with incomplete hematologic recovery [CRi] or CR with partial hematologic recovery [CRh])&#xD;
      after induction.&#xD;
&#xD;
      III. To estimate minimal residual disease (MRD) negativity after induction. IV. To estimate&#xD;
      MRD negativity after consolidation. V. To estimate CR after induction for Philadelphia&#xD;
      (Ph)-like ALL. VI. To estimate CR/CRi/CRh after induction for Ph-like ALL. VII. To estimate&#xD;
      MRD negativity after induction for Ph-like ALL. VIII. To estimate MRD negativity after&#xD;
      consolidation for Ph-like ALL. IX. To estimate leukemia-free survival (LFS) and overall&#xD;
      survival (OS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION: Patients receive venetoclax orally (PO) on days 1-14. Patients also receive&#xD;
      cytarabine intrathecally (IT) on day 1, prednisone PO twice daily (BID) on days 1-28,&#xD;
      vincristine intravenously (IV) on days 1, 8, 15 and 22, daunorubicin IV on days 1, 8, 15 and&#xD;
      22, pegaspargase intramuscularly (IM) or IV on day 4, and methotrexate IT on days 8 and 29&#xD;
      (and also on days 15 and 22 for central nervous system [CNS]3 patients) in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial&#xD;
      response (PR) after Induction proceed to Extended Induction. Patients with CR, CRi, or CRh&#xD;
      after Induction proceed to Consolidation.&#xD;
&#xD;
      EXTENDED INDUCTION: Patients receive venetoclax PO on days 1-7, prednisone PO BID on days&#xD;
      1-14, vincristine IV on days 1 and 8, daunorubicin IV on day 1, and pegaspargase IM or IV on&#xD;
      day 4 in the absence of disease progression or unacceptable toxicity. Patients with CR, CRi,&#xD;
      or CRh after Extended Induction proceed to Consolidation.&#xD;
&#xD;
      CONSOLIDATION: Patients receive venetoclax PO on days 1-14, cyclophosphamide IV on days 1 and&#xD;
      29, cytarabine IV or subcutaneously (SC) on days 1-4, 8-11, 29-32 and 36-39, mercaptopurine&#xD;
      PO on days 1-14 and 29-42, vincristine IV on days 15, 22, 43 and 50, pegaspargase IM or IV on&#xD;
      days 15 and 43, and methotrexate IT on days 1, 8, 15 and 22 (omit on days 15 and 22 for CNS3&#xD;
      patients) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, then every 3 months&#xD;
      for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after completion of treatment</time_frame>
    <description>Will be graded according to the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, frequency, probable association with the study treatment and reversibility or outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>During cycle 1 (4 weeks)</time_frame>
    <description>Defined as any toxicities that occur during cycle 1, per CTCAE version 5.0, and are considered at least possibly related to venetoclax or the combination of venetoclax and C10403. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, frequency, probable association with the study treatment and reversibility or outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) after induction +/- extended induction</measure>
    <time_frame>At week 4 or 6</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial confidence interval (CI) will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) after consolidation</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete response (CR) (CR/ CR with incomplete hematologic recovery [CRi]/ CR with partial hematologic recovery [CRh]) after induction +/- extended induction</measure>
    <time_frame>At week 4 or 6</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negativity after induction +/- extended induction</measure>
    <time_frame>At day 28</time_frame>
    <description>Defined as residual leukemia &lt; 0.01% by flow cytometry. Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negativity after consolidation</measure>
    <time_frame>At week 12</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) after induction +/- extended induction for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>At week 4 or 6</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) after consolidation for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete response (CR) (CR/ CR with incomplete hematologic recovery [CRi]/ CR with partial hematologic recovery [CRh]) after induction +/- extended induction for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>At week 4 or 6</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negativity after induction +/- extended induction for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>At week 4 or 6</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) negativity after consolidation for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL)</measure>
    <time_frame>At week 12</time_frame>
    <description>Will be estimated and the 95% Clopper Pearson binomial CI will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated using the Kaplan-Meier product-limit method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be estimated using the Kaplan-Meier product-limit method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>B Acute Lymphoblastic Leukemia</condition>
  <condition>Ph-Like Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given SC, IV or IT</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>Bw 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>L-Asparaginase with Polyethylene Glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>Oncaspar-IV</other_name>
    <other_name>PEG-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase (Enzon - Kyowa Hakko)</other_name>
    <other_name>PEGLA</other_name>
    <other_name>Polyethylene Glycol L-Asparaginase</other_name>
    <other_name>Polyethylene Glycol-L-Asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (venetoclax, C10403 regimen)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented informed consent of the participant and/or legally authorized&#xD;
             representative&#xD;
&#xD;
          -  Age between 18 and 54 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2&#xD;
&#xD;
          -  Histologically confirmed B-cell ALL according to World Health Organization criteria&#xD;
&#xD;
               -  Note: Lymphoblastic leukemia is included as long as there is bone marrow&#xD;
                  involvement&#xD;
&#xD;
          -  Newly diagnosed disease with &gt;= 5% blasts in the marrow&#xD;
&#xD;
          -  White blood cell count less than 25 x 10^9/L prior to initiation of venetoclax.&#xD;
             Cytoreduction with hydroxyurea or steroid or a single dose of intrathecal chemotherapy&#xD;
             prior to treatment may be required (performed within 14 days prior to day 1 of&#xD;
             protocol therapy unless otherwise stated)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease or&#xD;
             underlying leukemia, =&lt; 3 X ULN) (performed within 14 days prior to day 1 of protocol&#xD;
             therapy unless otherwise stated)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) =&lt; 2.5 x ULN (performed within 14 days prior to day 1&#xD;
             of protocol therapy unless otherwise stated)&#xD;
&#xD;
               -  Unless it is related to underlying leukemia&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) =&lt; 2.5 x ULN (performed within 14 days prior to day 1&#xD;
             of protocol therapy unless otherwise stated)&#xD;
&#xD;
               -  Unless it is related to underlying leukemia&#xD;
&#xD;
          -  Creatinine clearance of &gt;= 60 mL/min per 24 hour urine test or the Cockcroft-Gault&#xD;
             formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise&#xD;
             stated)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50%&#xD;
&#xD;
               -  Note: Echocardiogram to be performed within 42 days prior to day 1 of protocol&#xD;
                  therapy&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test.&#xD;
             (performed within 14 days prior to Day 1 of protocol therapy unless otherwise stated)&#xD;
&#xD;
               -  If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
                  pregnancy test will be required&#xD;
&#xD;
          -  Agreement by females and males of childbearing potential* to use an effective method&#xD;
             of birth control (non-hormonal) or abstain from heterosexual activity for the course&#xD;
             of the study through at least 3 months after the last dose of protocol therapy&#xD;
&#xD;
               -  Childbearing potential defined as not being surgically sterilized (men and women)&#xD;
                  or have not been free from menses for &gt; 1 year (women only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leukemia-based therapy with chemotherapy with the exception of:&#xD;
&#xD;
               -  Cytoreduction with steroid or hydroxyurea or a single dose of intrathecal&#xD;
                  chemotherapy is allowed before initiating the study&#xD;
&#xD;
          -  Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy&#xD;
&#xD;
          -  Subjects who have consumed grapefruit, grapefruit products, Seville oranges (including&#xD;
             marmalade containing Seville oranges) or Star fruit within 3 days prior to the first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Live vaccines&#xD;
&#xD;
          -  Philadelphia chromosome positive (Ph+; t(9;22)), MLL-rearrangement, t(12;21), and&#xD;
             t(1;19)&#xD;
&#xD;
          -  T cell ALL&#xD;
&#xD;
          -  Class III/IV cardiovascular disability according to the New York Heart Association&#xD;
             Classification. Subjects with controlled, asymptomatic atrial fibrillation can enroll&#xD;
&#xD;
          -  Parenchymal central nervous system (CNS) involvement requiring cranial radiation&#xD;
&#xD;
          -  Participants with clinically significant arrhythmia or arrhythmias not stable on&#xD;
             medical management within two weeks of enrollment&#xD;
&#xD;
          -  History of acute cardiovascular ischemic event, i.e., myocardial infarction or&#xD;
             unstable angina within 6 months of enrollment&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study agent&#xD;
&#xD;
          -  Clinically significant uncontrolled illness&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Other active malignancy&#xD;
&#xD;
          -  Females only: Pregnant or breastfeeding&#xD;
&#xD;
          -  Any other condition that would, in the Investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns with clinical&#xD;
             study procedures&#xD;
&#xD;
          -  Prospective participants who, in the opinion of the investigator, may not be able to&#xD;
             comply with all study procedures (including compliance issues related to&#xD;
             feasibility/logistics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibrahim T Aldoss</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ibrahim T. Aldoss</last_name>
      <phone>626-218-0589</phone>
      <email>ialdoss@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim T. Aldoss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

